Correlation Between Exagen and Xilio Development
Can any of the company-specific risk be diversified away by investing in both Exagen and Xilio Development at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Exagen and Xilio Development into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Exagen Inc and Xilio Development, you can compare the effects of market volatilities on Exagen and Xilio Development and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Exagen with a short position of Xilio Development. Check out your portfolio center. Please also check ongoing floating volatility patterns of Exagen and Xilio Development.
Diversification Opportunities for Exagen and Xilio Development
0.08 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Exagen and Xilio is 0.08. Overlapping area represents the amount of risk that can be diversified away by holding Exagen Inc and Xilio Development in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Xilio Development and Exagen is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Exagen Inc are associated (or correlated) with Xilio Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Xilio Development has no effect on the direction of Exagen i.e., Exagen and Xilio Development go up and down completely randomly.
Pair Corralation between Exagen and Xilio Development
Considering the 90-day investment horizon Exagen Inc is expected to under-perform the Xilio Development. But the stock apears to be less risky and, when comparing its historical volatility, Exagen Inc is 1.09 times less risky than Xilio Development. The stock trades about -0.15 of its potential returns per unit of risk. The Xilio Development is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest 105.00 in Xilio Development on October 5, 2024 and sell it today you would earn a total of 2.00 from holding Xilio Development or generate 1.9% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Exagen Inc vs. Xilio Development
Performance |
Timeline |
Exagen Inc |
Xilio Development |
Exagen and Xilio Development Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Exagen and Xilio Development
The main advantage of trading using opposite Exagen and Xilio Development positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Exagen position performs unexpectedly, Xilio Development can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xilio Development will offset losses from the drop in Xilio Development's long position.Exagen vs. Fonar | Exagen vs. Burning Rock Biotech | Exagen vs. Sera Prognostics | Exagen vs. Castle Biosciences |
Xilio Development vs. Connect Biopharma Holdings | Xilio Development vs. Tyra Biosciences | Xilio Development vs. RAPT Therapeutics | Xilio Development vs. Mineralys Therapeutics, Common |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Complementary Tools
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |